Home/Pipeline/Nipocalimab

Nipocalimab

Myasthenia Gravis

Phase 3Active

Key Facts

Indication

Myasthenia Gravis

Phase

Phase 3

Status

Active

Company

Johnson & Johnson

About Johnson & Johnson

Founded in 1886, Johnson & Johnson operates as a multinational healthcare corporation headquartered in New Brunswick, New Jersey. The company's pharmaceutical division, Janssen, is a global leader in oncology, immunology, and neuroscience with blockbuster drugs like Stelara, Darzalex, and Remicade. J&J combines deep scientific expertise with extensive global reach, serving patients in over 175 countries while maintaining one of the industry's strongest R&D pipelines.

View full company profile

Therapeutic Areas

Oncology Immunology Neuroscience Infectious Diseases Cardiovascular Metabolism

Other Myasthenia Gravis Drugs

Drug	Company	Phase	Status
Rozanolixizumab	UCB	Phase 3	Active
IMVT-1402	Roivant Sciences	Registrational	Active
KYV-101	Kyverna Therapeutics	Phase 1/2	Active, not yet recruiting
Descartes-08	Cartesian Therapeutics	Phase 2	Active